All News

Pharmaceutical Executive daily

In today's Pharmaceutical Executive Daily, Johnson & Johnson, Processa Pharmaceuticals, and Relation strike new deals spanning cell therapy, BTK inhibition, and AI-driven target discovery, Inizio Engage launches Connected Insights to turn medical information interactions into strategic intelligence, and a commentary argues pharma companies need to manage direct-to-patient sales as a core commercial channel rather than a side program.

Pharmaceutical Executive Daily

In today's Pharmaceutical Executive Daily, a commentary examines why fragmented software tooling causes scientific judgment to get lost across the biologics R&D pipeline, Replimune shares crash nearly 32 percent after FDA reviewers raise concerns about its melanoma therapy, and FDA approves Viatris's Gwyn Lo as a new once-weekly contraceptive patch.

Stock.adobe.com

In today's Pharmaceutical Executive Daily, FDA approves Otsuka's Simtriyo as the first NDSRI treatment for ADHD, argenx agrees to acquire Forte Biosciences for approximately $2.2 billion, and an AbbVie neuroscience researcher discusses the shift from symptom management to disease modification in Parkinson's research.

Pharmaceutical Executive Daily

In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a supply chain expert discusses how China's export controls are exposing vulnerabilities in the U.S. pharmaceutical supply chain, and a pharmacy benefits executive lays out a business case for more targeted employer-based GLP-1 coverage.